Forecasting the future of peptide manufacturing: CMC challenges in the GLP-1 era

Published: 21-Mar-2025
Regulatory

In this article, Torsten Wöhr, Chief Commercial Officer at Bachem, explores the future of peptide CMC manufacturing for GLP-1 therapies, including innovations in sustainable peptide production, purification and compliance

You need to be a subscriber to read this article.
Click here to find out more.

In peptide manufacturing, glucagon-like peptide-1 (GLP-1) receptor agonists are one of the most significant advancements in decades.1

These drugs are raising expectations for patient outcomes in metabolic and obesity treatments; they’re also being promoted globally, as seen in the cases of semaglutide- and tirzepatide-based drugs. 

Forecasting the future of peptide manufacturing: CMC challenges in the GLP-1 era

Although initially developed for diabetes management, these therapies garnered far-reaching attention when data showed additional benefits for cardiovascular health and weight management.

The approval of liraglutide for weight loss in 2014 was a milestone as it introduced a scientifically validated and reimbursable pharmaceutical product to the weight loss market.2

Since then, GLP-1 demand has skyrocketed. Further, clinical trials have uncovered new applications in areas such as sleep apnoea, addiction and, potentially, neurodegenerative diseases.3  

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Bachem
See more

You may also like

Regulatory

WHO pandemic agreement determined after three years of negotiation

Read more
Through the deal, WHO will promote a unified, global response to future pandemics, ensuring that national health systems are equipped to control future outbreaks

Trending Articles

  1. WHO pandemic agreement determined after three years of negotiation Through the deal, WHO will promote a unified, global response to future pandemics, ensuring that national health systems are equipped to control future outbreaks
  2. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  3. Common reasons why field certifiers fail accreditation Biosafety cabinets are the backbone of laboratory safety; however, many facilities encounter significant obstacles when using them, such as high energy consumption, difficulties with decontamination and inefficient filter replacement processes
  4. CARBOGEN AMCIS CARBOGEN AMCIS is a global Contract Development and Manufacturing Organization (CDMO) providing drug development and commercialization services to the pharmaceutical and biopharmaceutical industries at all stages of drug development.<br><br>Our capabilities include contract chemical process research and development, supply of Active Pharmaceutical Ingredients (APIs), and drug products for preclinical studies, clinical trials, and commercial use, as well as high-quality Cholesterol and Vitamin D analog products
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

Making Pharmaceuticals

29-30 April 2025 | Conference | Coventry, UK See all

You may also like

Regulatory

WHO pandemic agreement determined after three years of negotiation

Through the deal, WHO will promote a unified, global response to future pandemics, ensuring that national health systems are equipped to control future outbreaks
Manufacturing

Filters to protect ‘your people, process and product’ at Making Pharma 2025

Amazon Filters showcases sustainable filtration solutions for the pharmaceutical industry
Manufacturing

Common reasons why field certifiers fail accreditation

Biosafety cabinets are the backbone of laboratory safety; however, many facilities encounter significant obstacles when using them, such as high energy consumption, difficulties with decontamination and inefficient filter replacement processes
Regulatory

FDA US Agent Services, backed by former regulators and global expertise

If you need a trusted US Agent backed by regulatory experts, NSF can keep your US market entry on track
Sustainability

Chemspec Europe 2025 to showcase innovation in fine and speciality chemicals

Leading global trade fair returns to Cologne with a focus on sustainability, regulation, and R&D
Regulatory

How to handle regulatory authority warning letters

What should a company do when they receive a warning letter from the FDA? Find out in this article
Manufacturing

Excipients, nitrosamines and risk assessments – creating safer drugs - NOW ON DEMAND

Join us for an in-depth webinar where we’ll explore the complex interplay between excipients, nitrosamines and regulatory compliance – and discover key ways you can elevate your own approach to risk assessments and ensure product safety
Subscribe now